Navigation Links
Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA
Date:6/24/2009

AMSTERDAM, The Netherlands, June 24 /PRNewswire/ -- The U.S. Department of Energy's Pacific Northwest National Laboratory has signed an agreement with Avantium to enable the sale and delivery of an Avantium Flowrence(TM) parallel fixed bed reactor system. The Flowrence(TM) will allow PNNL to accelerate its catalyst research for infrastructure compatible biofuels and bioproducts.

PNNL is operated by Battelle for the U.S. Department of Energy. The Laboratory advances science and develops solutions for global challenges at the energy and environment nexus. PNNL scientists have extensive expertise in catalysis and reaction engineering, with particular focus on solutions for efficient use of bioproducts, converting biomass and renewable feedstocks to fuels and chemicals, and reducing environmental emissions.

The Avantium system will be housed in the Bioproducts, Sciences and Engineering Laboratory (BSEL). BSEL is a multipurpose research and development facility that includes operating space for all activities required to advance the science and engineering of processes for bio-based product manufacture. The building is located on the campus of Washington State University Tri-Cities Campus in Richland, Washington, approximately one mile south of the main campus of PNNL.

Tom van Aken, Chief Executive Officer of Avantium: "The sale of Flowrence(TM) platforms to a world leading research center such as PNNL is a recognition of the value of Avantium's proprietary high-throughput R&D technology. We are proud to provide our unique Flowrence technology to PNNL to help increase PNNL's R&D productivity significantly with our methodology."

Avantium's proprietary parallel fixed bed rector technology has been successfully applied for over 9 years in collaboration programs for gas, liquid and trickle flow applications (e.g. hydrotreating, VGO hydrocracking, selective oxidation and selective hydrogenation). The Flowrence(TM) is Avantium's proprietary commercially available parallel fixed bed reactor system. The system consists of 16 reactors (4 blocks of 4 reactors each) tailored to the clients applications enabling them to enhance their catalysis research and process optimization efforts. Flowrence(TM) enables users to test catalytic materials for a range of chemistries under industrial processing conditions, including high-temperature (up to 850 0C) and high-pressure reactions (up to 180 Bar).

Profile Avantium

Avantium is a leading technology company specialized in the area of advanced high-throughput R&D. The company develops and commercializes Furanics, a next generation biofuels and bioplastics, and develops improved forms of existing drugs. Avantium has demonstrated the value and commercial potential of its unique technology and knowledge by collaborating with leading companies in the energy, chemical and pharmaceutical industry. Avantium's customer base for its R&D services and systems offering consists of more than 70 companies worldwide, including market leaders such as BP, Shell, Sasol, Pfizer and GSK. Avantium has around 140 employees; its offices and headquarters are based in Amsterdam, the Netherlands.

Flowrence(TM)

For more information about Flowrence(TM), including downloads and pictures, please visit http://www.avantium.com/flowrence. Flowrence(TM) is a trademark of Avantium.

http://www.avantium.com


'/>"/>
SOURCE Avantium Technologies B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Avantium Completes EUR 18 Million Financing Round
2. Cosun and Avantium Announce Collaboration
3. Avantium Launches the Crystalline, a New Parallel System for Crystallization Research
4. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
5. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
6. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
7. Valeritas Hires Trade and Distribution Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
8. Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
9. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
10. PARI Respiratorys LC PLUS & PRONEB Ultra Deliver Dey, L.P.s New COPD Therapy; Perforomist Launched Yesterday
11. CompareNetworks Media Group Delivers CME/CE Through Acuity Medical Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... 16, 2017 , ... While art and science are often thought of as ... might think. A Mesh Is Also a Snare, a group exhibition presented by ... Esther Klein Gallery (EKG) on August 17 and run through September 30. An opening ...
(Date:8/15/2017)... Aug. 15, 2017 After spending the past two years ... crowdsourced data collection, GeneFo now offers this platform to healthcare stakeholders ... amplifying support, adherence, and data collection vis a vis their members, ... the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kenall, a leader in sealed ... stay tightly sealed and perform efficiently for years. The downlights are ideal for ... aren't enough, such as: hospitals; behavioral health facilities; cleanrooms; containment areas; food and ...
(Date:8/14/2017)... ... August 14, 2017 , ... Opal ... using USB or PCI Express, announced the release of SYZYGY™, a new open ... satisfy the need for a compact, low cost, low pin-count, high-performance connectivity solution ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
Breaking Biology News(10 mins):